TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02410096

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise challenge in a cold chamber
Description: Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise challenge in a cold chamber
Description: Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Methacholine challenge
Description: Nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine challenge
Description: Nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oil supplementation verum
Description: Patients and subjects will take double blind an oil supplementation with middle-chain and polyunsaturated fatty acids for four weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oil supplementation placebo
Description: Patients and subjects will take double blind sunflower oil for four weeks
Study: NCT03351439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: Group 2 - Zopiclone 7.5 mg orally, nightly for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Group 3 - Gabapentin 600 mg orally, 1 hour pre-operatively and 600 mg orally, 8 hours post-operatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex
Description: Group 4 - Celebrex 400 mg PO, 1 hour pre-operatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet
Description: Standard of Care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Percocet
Description: Standard of Care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Percocet
Description: Standard of Care
Study: NCT01019928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: 95 mg, oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: 95 mg, oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to AZD1386
Description: Placebo, oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to AZD1386
Description: Placebo, oral solution, single dose
Study: NCT03351439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Percocet
Description: Standard of Care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naprosyn
Description: Standard of Care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naprosyn
Description: Standard of Care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naprosyn
Description: Standard of Care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naprosyn
Description: Standard of Care
Study: NCT02945605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Vestibular Rehabilitation
Description: Two visits/week for a maximum of 5 weeks will be provided with the approximate duration for each visit estimated at 50-60 minutes. Consistent with a previously validated framework for exercise prescription in patients with concussion, the exercises provided by the treating therapist can be classified into five main exercise categories:~1. Eye-Head coordination, gaze stability and convergence exercises~2. Sitting balance~3. Standing static balance (i.e. feet-in-place)~4. Dynamic balance (feet moving, but not walking)~5. Ambulation (gait exercises)~6. Other exercises: Sport specific exercises, Canalith repositioning maneuvers are recorded as others

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard care as directed by a physician.
Study: NCT02553317

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Caplacizumab
Description: * First day of treatment: 10 mg intravenous (i.v.) injection prior to plasma exchange (PE) followed by a 10 mg subcutaneous (s.c.) injection (in the abdominal region) after completion of PE on that day.~* Subsequent days of treatment during PE: daily 10 mg s.c. injection (in the abdominal region) following PE.~* Treatment after PE period: daily 10 mg s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression.
Study: NCT02945605

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard care as directed by a physician.
Study: NCT03805503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine 1% Injectable Solution
Description: standard CSE procedure in outpatients for inguinal hernia. The first spinal dose of chloroprocaine 1% to start with is 50mg. This dose has been successfully used for spinal anesthesia in hernia repair outpatients to reach an adequate analgesia. 2,5 microgram of sufentanil will be added for prolongation of the analgesia. The testing interval is 2 mg.~Efficacy of the analgesia will be evaluated:~Successful : sensory block at or above T6 dermatome bilateral at the beginning of surgery without additional analgesia during surgery. Unsuccessful: sensory block under T6 dermatome bilateral and/or VAPS is more than 10 mm at the beginning of surgery what necessitates additional epidurals analgesia.~Patients who indicate an ineffective result will receive a rescue treatment by the administration of 5 ml chloroprocaine 3% epidural every 5 minutes with maximum of 30ml. When CSE fails, general anesthesia will be performed.
Study: NCT04057469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tulobuterol Hydrochloride
Description: The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.
Study: NCT02626936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
Study: NCT04057469

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal patch
Description: The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.
Study: NCT03426566

Intervention type: OTHER
Intervention: retrospective observational study with no intervention
Description: no intervention
Study: NCT02553317

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * First day of treatment: i.v. injection prior to PE followed by a s.c. injection (in the abdominal region) after completion of PE on that day.~* Subsequent days of treatment during PE: daily s.c. injection (in the abdominal region) following PE.~* Treatment after PE period: daily s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression.
Study: NCT04099849

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet-ZnBfR: Zinc biofortified rice-based diet
Description: Diet-ZnBfR: Zinc biofortified rice-based diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet-ZnBfR: Zinc biofortified rice-based diet
Description: Diet-ZnBfR: Zinc biofortified rice-based diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet- CR: Conventional rice-based diet
Description: Diet- CR: Conventional rice-based diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CR + Zn: Conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
Description: CR + Zn: Conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
Study: NCT04260061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: training systems
Description: Participants will receive 18 intervention sessions for about 6-9 consecutive weeks in a clinical setting (75 minutes per session, 2-3 sessions per week). For each intervention session, participants will first receive 10 minutes of warm-up followed by 50 minutes robotic-assisted training (robotic-assisted training includes 10 minutes passive training mode, 20 minutes active training mode, and 20 minutes robot-participant interactive training mode) and then 15 minutes of functional activity without robotic-assisted (content will be related to robotic-assisted training and will be based on the action function and preferences of the participants).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: training systems
Description: Participants will receive 18 intervention sessions for about 6-9 consecutive weeks in a clinical setting (75 minutes per session, 2-3 sessions per week). For each intervention session, participants will first receive 10 minutes of warm-up followed by 50 minutes robotic-assisted training (robotic-assisted training includes 10 minutes passive training mode, 20 minutes active training mode, and 20 minutes robot-participant interactive training mode) and then 15 minutes of functional activity without robotic-assisted (content will be related to robotic-assisted training and will be based on the action function and preferences of the participants).
Study: NCT02703987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented infant milk formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-fermented infant milk formula
Study: NCT00229229

Intervention type: OTHER
Group type: OTHER
Intervention: Low glycemic load diet
Description: A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment

Intervention type: OTHER
Group type: OTHER
Intervention: Canada Food Guide Diet
Description: A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment

Intervention type: OTHER
Group type: OTHER
Intervention: Low glycemic index diet
Description: A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment

Intervention type: OTHER
Group type: OTHER
Intervention: Low carbohydrate diet
Description: A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
Study: NCT03338868

Intervention type: OTHER
Intervention: Quality of life
Description: assessed by the Nottingham Health Profile

Intervention type: OTHER
Intervention: Quality of life
Description: assessed by the Nottingham Health Profile

Intervention type: OTHER
Intervention: Psychological Well-Being
Description: assessed by the Hospital Anxiety and Depression Scale

Intervention type: OTHER
Intervention: Psychological Well-Being
Description: assessed by the Hospital Anxiety and Depression Scale

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: Blood tests included serum glucose, triglyceride, high-density lipoprotein cholesterol (HDL-C), and uric acid levels. Blood samples were collected from the patients after one night of fasting.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: Blood tests included serum glucose, triglyceride, high-density lipoprotein cholesterol (HDL-C), and uric acid levels. Blood samples were collected from the patients after one night of fasting.
Study: NCT01409824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDSS
Description: Clinical Decision Support System
Study: NCT02626936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
Study: NCT01315002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal nicotine patch
Description: 7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: Placebo patch
Study: NCT02626936

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G4 Platinum glucose sensor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G4 Platinum glucose sensor
Study: NCT03436771

Intervention type: GENETIC
Intervention: JCAR017
Description: No drug is administered in this study. Patients who received JCAR017 in a previous trial will be evaluated in this trial for long-term safety and survival.

Intervention type: GENETIC
Intervention: JCARH125
Description: No drug is administered in this study. Patients who received JCARH125 in a previous trial will be evaluated in this trial for long-term safety and survival.
Study: NCT04576247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise
Description: The 12-week intervention will build upon an ongoing resistance exercise program for cancer patients and survivors at the University of Colorado's Anschutz Health and Wellness Center. Resistance exercise will be led by certified cancer exercise specialists who provide individualized exercise programs to cancer patients and survivors. Exercise sessions are progressive, target all major muscle groups, are 50 minutes in duration, and completed 2x/week.~The intervention will also include 3 self-directed moderate-intensity aerobic exercise sessions/week, building to 50 minutes at 60% heart rate maximum (determined at baseline). Target exercise will be achieved by a gradual progression of exercise duration over the first four weeks of the program.
Study: NCT01530555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit ATG, Thymoglobuline (Genzyme)
Description: 1. Rabbit ATG, Thymoglobuline® (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.~2. Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months
Study: NCT01372449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine will be initiated at 3 mg. The dose will be increased every week by 3 mg for a maximum of 12mg for subjects weighing ≥ 60kg, 9mg for subjects weighing ≥ 40 kg but \<60 kg, and 6 mg for subjects weighing ≥ 20 kg but \< 40kg.
Study: NCT02736877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumera Microscope with OCT RESCAN
Description: corneal transplantation guided by Lumera Microscope with OCT RESCAN

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Microscope
Description: corneal transplantation guided by Conventional Microscope
Study: NCT02626936

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accu Chek Combo insulin pump
Study: NCT03164421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: N-Acetylcysteine in clomiphene resistant pcos women

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine
Description: L-carnitine in clomiphene resistant pcos women
Study: NCT04191655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Definition Colonoscopy
Description: A colonoscopy that used high definition (HD) camera
Study: NCT01372449

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03267771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone Suppositories Vaginal
Description: progesterone vaginal suppository

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone Oral Tablet
Description: oral progesterone drug

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: doppler ultrasound
Description: pulsed doppler ultrasound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: doppler ultrasound
Description: pulsed doppler ultrasound
Study: NCT02238288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminocaproic acid
Description: Crushed tablet in the dental socket

Intervention type: OTHER
Group type: OTHER
Intervention: Routine dental care
Description: Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes

Intervention type: DRUG
Group type: OTHER
Intervention: lidocaine and epinephrine
Description: 2%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine and epinephrine
Description: 2%

Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol
Description: 750 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 750 mg
Study: NCT02098057

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten Healthy
Description: Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks.
Study: NCT00444912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF plus plerixafor
Description: Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥5\*10\^6 CD34+ cells/kg were collected.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Participants were given a weekly dose of rituximab 375mg/m2 by intravenous infusion for 1 week prior to and continuing until 2 weeks after the first dose of G-CSF.
Study: NCT02098057

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio~Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks.
Study: NCT03548974

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment group 1
Description: The ms-intakt/MOTOmed-intervention is a home-based program using the MOTOmed movement trainer: 12 week passive, motor-driven movement therapy followed by 12 weeks of intermittent active and passive training after the 3month assessment. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. Therapists aimed at eliciting a BORG Feedback of between 10 (fairly light) and 15 (hard). The exercise training was home-based and supervised via the internet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment group 2
Description: The subjects assigned to interventiongroup2 started with 12 weeks intermittent active and passive training followed by 12 weeks of no intervention (Wash out phase)
Study: NCT00400439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalcetrapib (RO4607381)
Description: 900mg po daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: po daily for 24 weeks
Study: NCT02348580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child centered teaching of life-skills
Description: The intervention includes five core components: (1) personal understanding and exploration, (2) rights and responsibilities, (3) savings and spending, (4) planning and budgeting, and (5) social and financial enterprise. The training and curriculum are both manualized. The curriculum is in English and is regionally specific (for Anglophone Africa) and has been contextualized for Rwanda. The minimum hours required by Aflatoun's fidelity guide is 20 hours which includes 10 hours of curriculum lesson and 10 hours of learning activities (savings groups, social and financial projects, club activities etc).
Study: NCT02358993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methenamine hippurate
Description: A urinary antiseptic used for prevention of UTI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: An antibiotic used for treatment and prevention of UTI
Study: NCT04133350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Patient Engagement
Description: The APE intervention will be delivered through a patient-facing application and website called myAir, which provides patients with access to their own usage data, educational tips, and coaching.
Study: NCT04362306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planned Intervention
Description: Intervention with a member of the medical physics team to review the process of simulation, treatment planning, and subsequent treatment. This meeting will last approximately 15 minutes and at this time, the team member will explain that they are the primary resource for all the technical aspects related to the patient's treatment. Additionally, they will identify and address any concerns that patients or their caregivers have with radiation treatment and the patient will be shown the simulation infographic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No planned intervention
Description: Anxiety and patient satisfaction questionnaires will be completed prior to CT simulation.
Study: NCT01822665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Liquid gelation capsules or tablets of 400 mg strength

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Liquid gelation capsules or tablets of 400 mg strength

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol fast dissolving tablets of 500 mg strength

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT01547156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention group
Study: NCT01736033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 1 tablet(0.2mg) orally q.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamsulosin
Description: 1 tablet(0.2mg) orally q.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride
Description: 1 tablet(5mg) orally q.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet(0.2mg) orally q.d.